Product involved: Mucosamin Spray
Treatment of symptomatic Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplantation (HSCT)
Study:
Treatment of symptomatic Oral Mucositis in Patients Undergoing Haematopoietic Stem Cell Transplantation (HSCT)
Design:
137 patients were divided in 4 groups:
- Group A (37 patients): all received a complete session of professional oral health care (POHC) and Mucosamin spray on mucositis lesions 3-4 times a day after a meal.
- Group B (32 patients): all received a complete session of professional oral health care (POHC) and Clorexidine 0.20%.
- Group C (34 patients): received Mucosamin spray on mucositis lesions 3-4 times a day after a meal.
- Group D (34 patients): received only Clorexidine 0.20% on oral mucositis lesions.
Measurements:
- VAS scale.
- Score for oral mucositis – WHO grade scale for oral mucositis: light mucositis WHO grade 1 and 2; severe mucositis WHO grade 3 and 4.
Oral mucositis prevalence
WHO grade of OM
OMAS grade of OM
Oral mucositis gravity
Clinical Results
• Treated patients with Mucosamin Spray developed less severe mucositis.
• Treated patients with Mucosamin Spray resolved the mucositis in less time.
• Maximum pain, measured with VAS scale, was lower in patients treated with Mucosamin Spray.
